Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...

Cassava Sciences has faced a lot of scrutiny, with key figures resigning and the company settling an SEC penalty. Read what ...

Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

Please refer to Cassava Sciences' recent filings with the SEC, including Forms 10-K and 10-Q for a description of the factors ...

SEC adopts EDGAR Next - As outlined in this October 22 Cooley alert, the Securities and Exchange Commission (SEC) adopted final ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Cassava Sciences plans to pay a $40 million SEC investigation settlement, which has been placed in escrow. The company estimates its year-end cash balance to range from $117 to $127 million.

Cassava Sciences plans to pay a $40 million SEC investigation settlement, which has been placed in escrow. The company estimates its year-end cash balance to range from $117 to $127 million. The press ...

Detailed price information for Cassava Sciences Inc (SAVA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Cassava Sciences Inc (SAVA-Q) from The Globe and Mail including charting and trades.